Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

REGISTER for free or LOG IN to view this content

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Clinical Cardiology

Prevention

Clinical Pharma

Presentation

AHA 2024

Up Next

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

More slides +

Presentation Cardiovascular Interventions 2024

Bifurcation stenting techniques: Step-by-Step

Presenter: Emmanouil S. Brilakis

November 11, 2024

Presentation Cardiovascular Interventions 2024

Mechanical Circulatory Support: Here Are the Options and Here's How to Match Them to the Right Patient

Presenter: James Hermiller

November 11, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.